Startup · $14m raised
Dunedin
Every investor coverage indicates participated in a round Amaroq Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Unnamed stage | - |
| Cure Kids Ventures | Unnamed stage | - |
| NZ Innovation Booster | Unnamed stage | - |
| Otago Innovation Ltd | Unnamed stage | - |
| University of Otago | Unnamed stage | - |
Investors whose own portfolio pages list Amaroq Therapeutics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Tenmile | its portfolio page ↗ |
Companies Amaroq Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Amaroq Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Brandon Capital's site announces it led $14m for Amaroq Therapeutics, an Otago spinout developing RNA-based cancer treatments — the firm's first deal as a government-backed incubator. The piece also recalls Kea Therapeutics' shutdown.
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.
University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio